Achievement of three year remission with bevacizumab and irinotecan in recurrent glioblastoma multiforme: A case report

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 15-21

  Vivekanandarajah, Abhirami ^a   Krishnarasa, Balakumar ^a   Mourad, Mervat ^a   Aoun, Nelly ^a   Odaimi, Marcel ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Bevacizumab; Irinotecan; Recurrent glioblastoma multiforme

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CLINDAMYCIN; DEXAMETHASONE; ETIRACETAM; IRINOTECAN; TEMOZOLOMIDE;

ACNE; ADJUVANT THERAPY; ADULT; ARTICLE; BLURRED VISION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; GLIOBLASTOMA; HEADACHE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SALVAGE THERAPY; SEIZURE; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR REGRESSION;

EID: 79958022165     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6525     Document Type: Article

References (20)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10-4.
4. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112:1139-46.
5. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-8.
6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 987-96.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
8. Hau P, Baumgart U, Pfeifer K, et al. Salvage therapy in patients with glioblastoma: is there any benefit? Cancer. 2003;98:2678-86.
9. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21:607-14.
10. Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998; 42:709-20; discussion 720-03.
11. Harsh GRT, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987; 21:615-21.
12. Kappelle AC, Postma TJ, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118-20.
13. Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008;22:452-5.
14. Hamberg P, de Jong FA, Brandsma D, Verweij J, Sleijfer S. Irinotecaninduced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol. 2008;47:974-8.
15. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183-8.
16. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003;97:2381-6.
17. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17: 1516-25.
18. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8:189-93.
19. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27:4733-40.
20. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91:329-36.